Home › Funds › BARCLAYS PLC › VRTX

BARCLAYS PLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

BARCLAYS PLC reported holding 733,274 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$364.2M, representing 0.41% of its reported portfolio and ranking #47 among its reported holdings. BARCLAYS PLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)733.27K sh
Reported value held$364.24M
Portfolio Weight0.41%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BARCLAYS PLC's VRTX position evolved

BARCLAYS PLC first disclosed a stake in VRTX in Q3 2023 at 1,000 shares (US$348K). The position peaked in Q2 2026 at 733,274 shares, worth US$364.2M. Across 12 filings, BARCLAYS PLC increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 733,274 shares valued at US$364.2M — an increase of 711,574 shares quarter over quarter.. Notable position changes include a 1039% increase in Q2 2024 (shares were roughly flat over the following quarter), a 442% increase in Q1 2026 (shares rose 11% over the following quarter), a 3279% increase in Q2 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.00K $347.74K New
Q4 2023 1.20K $488.27K Add
Q1 2024 3.30K $1.38M Add
Q2 2024 37.60K $17.62M Add
Q3 2024 16.00K $7.44M Reduce
Q4 2024 27.90K $11.24M Add
Q1 2025 4.00K $1.94M Reduce
Q2 2025 4.00K $1.78M Hold
Q3 2025 4.00K $1.57M Hold
Q4 2025 4.00K $1.81M Hold
Q1 2026 21.70K $9.69M Add
Q2 2026 733.27K $364.24M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has BARCLAYS PLC held VRTX?

BARCLAYS PLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BARCLAYS PLC's current position in VRTX?

As of Q2 2026, BARCLAYS PLC holds 733.27K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $364.24M, representing 0.41% of its reported portfolio and ranking #47.

Has BARCLAYS PLC been buying or selling VRTX?

In the latest 13F filing (Q2 2026), BARCLAYS PLC increased its position in VRTX. The position peaked in Q2 2026 at 733.27K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.